Search Results

You are looking at 31 - 40 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Frank Xiaoqing Liu, Kirstin Heinrich, Catarina Neves, Ying Zheng, and Adam Kasle

Background: Avelumab in combination with axitinib (A+Ax) was approved by the FDA for the first-line (1L) treatment of patients with advanced renal cell carcinoma (RCC). We aimed to evaluate the financial impact of adding A+Ax as a 1L treatment

Full access

CLO24-077: Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Immunotherapy: An Analysis of the National Cancer Database (NCDB)

Insija Ilyas Selene, Feitong Lei, Amina Dhahri, Jennifer C. Torres Yee, Bin Huang, Jemin Jose, and Zin Myint

Background: The landscape of metastatic renal cell carcinoma (mRCC) treatment has witnessed significant transformations with the emergence of immunotherapy-based combination regimens (IO-X), including IO-IO and IO-TKI. However, the role of

Full access

Biomarker Testing for Immunotherapy

Jarushka Naidoo

biomarker: key limitations. Abbreviations: IC, immune cells; IO, immuno-oncology; N/A, not applicable; NSCLC, non–small cell lung cancer; RCC, renal cell carcinoma; TC, tumor cells. Adapted from Drake et al, ASCO 2018. Immunogenic Tumor Biomarkers “We've all

Full access

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, CGC, Lydia J. Hammond, and Griselda Zuccarino-Catania

disease. 1 Approximately 85% of kidney tumors are renal cell carcinoma (RCC), and approximately 70% are of clear cell histology. 2 – 4 Histologic diagnosis of RCC is established after surgical removal of renal tumors or after biopsy. For therapy

Full access

CLO24-080: Association Between Primary Tumor Size and Prognosis in De Novo Metastatic Renal Cell Carcinoma in Patients Who Underwent First Line Immunotherapy-Based Therapy: Real World Data Analysis

Insija Ilyas Selene, Roshmita Bardhan, Rani Jayswal, Amina Dhahri, Jennifer C. Torres Yee, Heidi L. Weiss, Kimberly D. Ratliff, and Zin Myint

Current treatment approaches for metastatic renal cell carcinoma (mRCC) are immunotherapy (IO) combinations such as (IO + IO) vs. (IO + tyrosine kinase inhibitor [TKI]) depending on IMDC risk factors, focusing on performance status and laboratory

Full access

BPI20-013: A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Lukman Tijani, and Shabnam Rehman

for advanced renal cell carcinoma (aRCC). When used individually, both ICIs and VEGFis have significant mucocutaneous toxicities. We performed a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the

Full access

BPI20-012: Relative Risk of Various Endocrinopathies Associated With the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: a Systematic Review and Meta-Analysis

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Somedeb Ball, Fred Hardwicke, Lukman Tijani, and Shabnam Rehman

Background: While immune checkpoint inhibitors (ICI) are an important addition to the armamentarium in the fight against advanced renal cell carcinoma (aRCC), ICIs are associated with significant endocrine toxicities. We conducted a meta

Full access

CLO20-057: A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma

Miguel Angel Quirch, Nusrat Jahan, Meda Srikala, Fred Hardwicke, and Lukman Tijani

In recent randomized clinical trials (RCTs), immune checkpoint inhibitor (ICI) and anti-angiogenic tyrosine kinase inhibitor (VEGFi) combinations have been investigated as front-line therapy in advanced renal cell carcinoma (aRCC). We conducted a

Full access

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Andrew Gunn, Naomi Haas, Michael Johnson, Payal Kapur, Jennifer King, Christos Kyriakopoulos, Elaine T. Lam, Primo N. Lara, Clayton Lau, Bryan Lewis, David C. Madoff, Brandon Manley, M. Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Jeffrey Sosman, Randy Sweis, Matthew Zibelman, Ryan Schonfeld, MaryElizabeth Stein, and Lisa A. Gurski

Scientific Affairs, LLC; and Seagen. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. Overview Renal cell carcinoma

Full access

Controversies in the Surgical Management of Renal Cancer

Michael P. Porter and Paul H. Lange

( 6 Pt 1 ): 2181 – 2185 ; quiz 2435 . 3 Stephenson AJ Chetner MP Rourke K . Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy . J Urol 2004 ; 172 : 58 – 62 . 4